News, events & publications

Latest news
2 Jun 2026 · Announcement

Launch of TechBio firm, Lucera, brings decision intelligence to drug development, making it more predictable, more evidence-grounded, and more efficient

Heidelberg, Germany – June 2, 2026 – Lucera GmbH, a TechBio company utilizing its proprietary technology to transform pharmaceutical R&D and enhance development efficacy and efficiency through unique decision intelligence, today announced the launch of its operations. The newly formed corporation is funded by a consortium…

Read the announcement ›
Upcoming events
Publications

27 publications

  1. 2023 Rewiring Drug Research and Development through Human Data-Driven Discovery (HD3) Jackson DB, Racz R, Kim S, et al. Pharmaceutics · DOI 10.3390/pharmaceutics15061673
  2. 2023 Whole patient knowledge modeling of COVID-19 symptomatology reveals common molecular mechanisms Brock S, Jackson DB, Soldatos TG, et al. Frontiers in Molecular Medicine · DOI 10.3389/fmmed.2022.1035290
  3. 2022 A case study of a patient-centered reverse translational systems-based approach to understand adverse event profiles in drug development Kim S, Lahu G, Vakilynejad M, et al. Clinical and Translational Science · DOI 10.1111/cts.13219
  4. 2022 Advancing drug safety science by integrating molecular knowledge with post-marketing adverse event reports Soldatos TG, Kim S, Schmidt S, et al. CPT: Pharmacometrics & Systems Pharmacology · DOI 10.1002/psp4.12765
  5. 2022 Application of a patient-centered reverse translational systems-based approach to understand mechanisms of an adverse drug reaction of immune checkpoint inhibitors Kim S, Lahu G, Vakilynejad M, et al. Clinical and Translational Science · DOI 10.1111/cts.13254
  6. 2022 The COVID-19 explorer—An integrated, whole patient knowledge model of COVID-19 disease Brock S, Soldatos TG, Jackson DB, et al. Frontiers in Molecular Medicine · DOI 10.3389/fmmed.2022.1035215
  7. 2022 Upregulation of miRNA-200c during disease progression in COVID-19 patients van de Sand L, Braß P, Gregorius J, et al. Journal of Clinical Medicine · DOI 10.3390/jcm12010283
  8. 2021 Target Adverse Event Profiles for Predictive Safety in the Postmarket Setting Schotland P, Racz R, Jackson DB, et al. Clinical Pharmacology & Therapeutics · DOI 10.1002/cpt.2074
  9. 2020 Public Adverse Event Data Insights into the Safety of Pembrolizumab in Melanoma Patients Schaefer A, Sachpekidis C, Diella F, et al. Cancers · DOI 10.3390/cancers12041008
  10. 2019 Adverse Event Circumstances and the Case of Drug Interactions Soldatos TG, Jackson DB Healthcare · DOI 10.3390/healthcare7010045
  11. 2019 Radioimmunotherapy in Non-Hodgkin’s Lymphoma: Retrospective Adverse Event Profiling of Zevalin and Bexxar Sachpekidis C, Jackson DB, Soldatos TG Pharmaceuticals · DOI 10.3390/ph12040141
  12. 2018 A Neural Autoencoder Approach for Document Ranking and Query Refinement in Pharmacogenomic Information Retrieval Pfeiffer J, Broscheit S, Gemulla R, Göschl M Proceedings of the BioNLP 2018 workshop · DOI 10.18653/v1/W18-2310
  13. 2018 Association Between Serotonin Syndrome and Second-Generation Antipsychotics via Pharmacological Target-Adverse Event Analysis Racz R, Soldatos TG, Jackson D, Burkhart K Clinical and Translational Science · DOI 10.1111/cts.12543
  14. 2018 In Silico Profiling of Clinical Phenotypes for Human Targets Using Adverse Event Data Soldatos TG, Taglang G, Jackson DB High-throughput · PMID 30477159
  15. 2018 Target-Adverse Event Profiles to Augment Pharmacovigilance: A Pilot Study With Six New Molecular Entities Schotland P, Racz R, Jackson D, et al. CPT: Pharmacometrics & Systems Pharmacology · DOI 10.1002/psp4.12356
  16. 2016 Improving drug safety with a systems pharmacology approach Schotland P, Bojunga N, Zien A, et al. European Journal of Pharmaceutical Sciences · DOI 10.1016/j.ejps.2016.06.009
  17. 2016 Use of “big data” in drug discovery and clinical trials Taglang G, Jackson DB Gynecologic Oncology · DOI 10.1016/j.ygyno.2016.02.022
  18. 2015 Data Mining FAERS to Analyze Molecular Targets of Drugs Highly Associated with Stevens-Johnson Syndrome Burkhart KK, Abernethy D, Jackson D Journal of Medical Toxicology · DOI 10.1007/s13181-015-0472-1
  19. 2015 Erythropoietin Stimulates Tumor Growth via EphB4 Pradeep S, Huang J, Mora EM, et al. Cancer Cell · DOI 10.1016/j.ccell.2015.09.008
  20. 2015 How to learn about gene function: text-mining or ontologies? Soldatos TG, Perdigão N, Brown NP, et al. Methods · DOI 10.1016/j.ymeth.2014.07.004
  21. 2014 Drugs Highly Associated with Infusion Reactions Reported using Two Different Data-mining Methodologies Keith K Burkhart PWM Journal of Blood Disorders & Transfusion · DOI 10.4172/2155-9864.1000195
  22. 2013 Src activation by β-adrenoreceptors is a key switch for tumour metastasis Armaiz-Pena GN, Allen JK, Cruz A, et al. Nature communications · Reference on file
  23. 2012 A Scatter-Based Prototype Framework and Multi-Class Extension of Support Vector Machines Jenssen R, Kloft M, Zien A, et al. PLoS ONE · DOI 10.1371/journal.pone.0042947
  24. 2012 Biggest challenges in bioinformatics Molecular Health catalogue / legacy record · Reference on file
  25. 2011 Using graph theory to analyze biological networks Pavlopoulos GA, Secrier M, Moschopoulos CN, et al. BioData Mining · DOI 10.1186/1756-0381-4-10
  26. 2010 Drug profiling: knowing where it hits Merino A, Bronowska AK, Jackson DB, Cahill DJ Drug Discovery Today · DOI 10.1016/j.drudis.2010.06.006
  27. 2010 LAITOR—Literature Assistant for Identification of Terms co-Occurrences and Relationships Barbosa-Silva A, Soldatos TG, Magalhães IL, et al. BMC Bioinformatics · DOI 10.1186/1471-2105-11-70